In studies of nonalcoholic fatty liver disease (NAFLD), Tan IIA was found to improve NAFLD by targeting PPAR-γ and TLR4, thereby reducing lipids and oxidative stress, a strategy that may form the basis for novel NAFLD therapies (Huang et al., 2019). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.